Is Hims and Hers Health Stock a Buy After Its Latest Dip?

Hims & Hers raised full-year revenue guidance to $2.8 billion-$3.0 billion, but cut adjusted EBITDA guidance to $275 million-$350 million from $300 million-$375 million, signaling significant margin compression. Q1 revenue rose 4% year over year to $608.1 million, but adjusted EBITDA fell 51% to $44.3 million and EPS swung to a $0.40 loss from a $0.20 profit. The stock may get optionality from potential peptide approval if the FDA ban is lifted, but that remains speculative and regulation-dependent.

Analysis

HIMS is transitioning from a high-margin direct-to-consumer software-like healthcare model toward a lower-margin distribution model. The key second-order issue is not simply that gross margin compresses, but that operating leverage becomes much harder to sustain when customer acquisition is subsidized by a branded-drug wedge; the market is likely underestimating how quickly the lifetime value / CAC math can deteriorate if cross-sell attach rates do not improve within the next 2-3 quarters.

The upside case hinges on regulatory optionality, not current fundamentals. If peptide access expands, HIMS could get an incremental demand shock with strong consumer pull-through, but that would also invite faster competitive response from telehealth peers and pharmacy-channel intermediaries, likely neutralizing some pricing power. In other words, approval could lift top-line growth while still leaving the business closer to a low-double-digit EBITDA margin ceiling than the market may assume.

For NVO, the relationship is more subtle: HIMS’s volume push may support demand discovery and patient conversion, but it also pressures branded GLP-1 economics by training consumers toward lower-friction access and price transparency. The main risk to the short thesis is a policy headline on peptides, which would hit immediately in the multiple before fundamentals can validate. Absent that catalyst, the next 1-2 quarters likely remain a sentiment trap, with every revenue beat increasingly discounted if EBITDA continues to reset lower.

Key Decisions for Investors

• Avoid owning HIMS outright into the next earnings cycle unless you are explicitly underwriting a regulatory catalyst; the stock now trades like a call option on peptide approval, not a fundamental growth compounder.
• For tactical exposure, use a call spread on HIMS rather than stock: buy 3-6 month upside only if you expect a peptide policy headline within that window; otherwise theta and margin-reset risk dominate.
• Pair trade: short HIMS / long NVO on any strength. The market is pricing HIMS as a beneficiary of branded obesity demand, but the more durable economics likely accrue to the supplier with regulatory and manufacturing leverage.
• If you want to express a bearish view, wait for post-rally entry rather than chasing weakness; the better setup is after a speculative bounce, when implied volatility compresses and the business-quality gap is clearer.
• Risk control: cover any HIMS short immediately on credible FDA or HHS movement on peptides, because the rerating would be fast and the stock can gap 15-25% on policy news.